Австралия - английский - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - olanzapine, quantity: 7.5 mg - tablet, film coated - excipient ingredients: triacetin; purified talc; hyprolose; isopropyl alcohol; lactose monohydrate; mannitol; titanium dioxide; magnesium stearate; purified water; pectin; propylene glycol; butan-1-ol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - olanzapine is indicated for the treatment of schizophrenia and related psychoses.,olanzapine alone or in combination with lithium or valproate is indicated for the short-term treatment of acute manic episodes associated with bipolar i disorder.,olanzapine is indicated for preventing recurrence of manic, mixed or depressive episodes in bipolar i disorder.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 172.704 mg (equivalent: quetiapine, qty 150 mg) - tablet, film coated - excipient ingredients: hypromellose; magnesium stearate; iron oxide yellow; povidone; macrogol 400; lactose monohydrate; sodium starch glycollate type a; titanium dioxide; calcium hydrogen phosphate dihydrate; microcrystalline cellulose - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Австралия - английский - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 172.704 mg (equivalent: quetiapine, qty 150 mg) - tablet, film coated - excipient ingredients: povidone; titanium dioxide; microcrystalline cellulose; lactose monohydrate; magnesium stearate; sodium starch glycollate type a; macrogol 400; iron oxide yellow; calcium hydrogen phosphate dihydrate; hypromellose - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Австралия - английский - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 115.136 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: iron oxide yellow; magnesium stearate; microcrystalline cellulose; sodium starch glycollate type a; hypromellose; titanium dioxide; calcium hydrogen phosphate dihydrate; lactose monohydrate; macrogol 4000; povidone - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Австралия - английский - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 230.272 mg (equivalent: quetiapine, qty 200 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; povidone; sodium starch glycollate type a; hypromellose; magnesium stearate; calcium hydrogen phosphate dihydrate; macrogol 400; lactose monohydrate; titanium dioxide - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Австралия - английский - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 115.136 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: macrogol 4000; calcium hydrogen phosphate dihydrate; magnesium stearate; titanium dioxide; microcrystalline cellulose; lactose monohydrate; hypromellose; povidone; sodium starch glycollate type a; iron oxide yellow - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Австралия - английский - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 115.136 mg (equivalent: quetiapine, qty 100 mg) - tablet, film coated - excipient ingredients: hypromellose; macrogol 4000; microcrystalline cellulose; calcium hydrogen phosphate dihydrate; povidone; iron oxide yellow; titanium dioxide; lactose monohydrate; sodium starch glycollate type a; magnesium stearate - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Австралия - английский - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 345.408 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; titanium dioxide; hypromellose; macrogol 400; calcium hydrogen phosphate dihydrate; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; povidone - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Австралия - английский - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 28.784 mg (equivalent: quetiapine, qty 25 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; titanium dioxide; magnesium stearate; iron oxide red; microcrystalline cellulose; macrogol 400; sodium starch glycollate type a; calcium hydrogen phosphate dihydrate; povidone; hypromellose; iron oxide yellow - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia

Австралия - английский - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - quetiapine fumarate, quantity: 345.408 mg (equivalent: quetiapine, qty 300 mg) - tablet, film coated - excipient ingredients: titanium dioxide; macrogol 400; microcrystalline cellulose; sodium starch glycollate type a; magnesium stearate; lactose monohydrate; hypromellose; calcium hydrogen phosphate dihydrate; povidone - quetiapine is indicated for:,bipolar disorder,adults,? maintenance treatment of bipolar i disorder, as monotherapy or in combination with lithium or sodium valproate, for the prevention of relapse/recurrence of manic, depressive or mixed episodes,? treatment of depressive episodes associated with bipolar disorder (see dosage and administration),? treatment of acute mania associated with bipolar i disorder as monotherapy or in combination with lithium or sodium valproate,children/adolescents aged 10 to 17 years,? monotherapy treatment of acute mania associated with bipolar i disorder,schizophrenia (adults and adolescents aged 13 to 17 years),? treatment of schizophrenia